Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc., as indicated in the metadata) for the reporting period ending August 21, 2009, covering events occurring on August 18, 2009. The filing addresses the company's status regarding its listing on the NYSE Amex, LLC.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance and listing status rather than financial performance metrics.
Material Changes
- Listing Plan Approval: On August 18, 2009, the NYSE Amex accepted the Company's plan to regain compliance with continued listing requirements, averting immediate delisting.
- Remediation of Deficiency: The Exchange approved the listing of securities issued pursuant to the June 30, 2009 offering, thereby remedying a Section 301 deficiency previously reported on August 13, 2009.
Outlook, Risks, and Management Commentary
- Compliance Conditions: Continued listing is conditional upon the Company making a public announcement of non-compliance with a target completion date of December 6, 2010, and providing quarterly updates on plan initiatives.
- Delisting Risk: The Exchange staff will review progress; failure to show progress consistent with the plan may result in the commencement of delisting proceedings.
- Management Stance: Management anticipates complying with the plan requirements and the associated reporting obligations.
Investor Verification Checklist
- Verify the Company's progress against the plan milestones by the December 6, 2010 target date.
- Confirm the issuance of the required public announcement regarding non-compliance status.
- Monitor future quarterly filings for updates on the initiatives outlined in the compliance plan.
- Review the attached press release (Exhibit 99.1) for specific details on the non-compliance disclosure.